Report date: Wednesday, July 22, 2026, before the market opens
Conference call: 8:30 a.m. Eastern Time
Ticker: CME
CME enters the report with a relatively modest near-term earnings hurdle but a much more consequential strategic debate.
Q2 trading activity was strong in absolute terms—CME recorded its second-highest second-quarter average daily volume—but it declined slightly from the exceptional Q2 2025 comparison. Accordingly, consensus calls for roughly flat revenue and a small decline in adjusted EPS. The more important questions concern CME's pricing and revenue capture, expense trajectory, and whether newly permitted perpetual futures represent a lasting threat to its exchange moat.
Based on FactSet estimates reported by TradingView, consensus is approximately:
| Metric | Q2 2026 consensus | Q2 2025 actual | YoY |
|---|---|---|---|
| Revenue | $1.70 billion | $1.69 billion | ~Flat |
| Adjusted EPS | $2.93 | $2.96 | ~(1%) |
CME beat consensus by relatively small amounts in each of the preceding four quarters, so another modest beat may not be enough by itself to drive the shares. (tradingview.com)
CME has disclosed Q2 average daily volume of 29.8 million contracts, down approximately 1% from 30.2 million in Q2 2025. The composition was mixed:
June finished strongly, with total ADV up 19% year over year to a June record of 30.6 million. Equity-index ADV rose 54%, interest-rate ADV increased 17%, international ADV grew 17%, and cryptocurrency ADV increased 76%. (cmegroup.com)
The central takeaway is that Q2 was not weak, but it did not repeat Q1's extraordinary conditions. First-quarter ADV reached 36.2 million, producing record revenue of $1.88 billion and adjusted EPS of $3.36. (cmegroup.com)
CME's total volume fell only slightly, but the product mix may limit clearing-fee revenue:
Equity strength and continued micro-product adoption are strategically favorable, but they can depress the reported rate per contract. Investors should therefore judge the quarter on total clearing and transaction fees, not RPC in isolation.
A good outcome would be an RPC decline that is fully explained by mix and is accompanied by stable-to-higher transaction revenue. A more concerning result would be weak RPC combined with little evidence that incremental volume is compensating for the lower rate.
With ADV already disclosed, the biggest modeling swing factor is monetization.
Consensus revenue of $1.70 billion is approximately flat year over year and roughly 10% below Q1. That appears reasonable given the lower Q2 ADV, but there is room for upside if:
Investors should compare the change in transaction-fee revenue with the roughly 1% decline in total ADV. A substantially larger revenue decline would suggest an unfavorable product/customer mix.
Q1 market-data revenue reached a record $224 million, up 15%, marking the company's 32nd consecutive quarter of year-over-year growth. Management attributed the result to professional subscriber growth, simulated-trading usage, product expansion, policy changes and pricing.
This business is important because it reduces CME's dependence on quarter-to-quarter volatility. Another double-digit growth result would reinforce the view that market data has become a durable structural growth engine rather than merely an ancillary exchange service.
Conversely, a sharp deceleration would make the broadly flat transaction-volume comparison more visible in consolidated revenue.
CME's Q1 adjusted operating margin reached a record 72.8%, with approximately $200 million of a $238 million revenue increase flowing through to adjusted net income.
Management maintained 2026 expense guidance of approximately $1.695 billion excluding license fees after reporting roughly $405 million in Q1. Simple arithmetic implies an average of about $430 million per quarter for the remainder of the year, although actual quarterly timing will vary.
Expenses are likely to rise sequentially because of:
The key is whether these investments remain within the annual framework. A reaffirmation of the $1.695 billion target would be reassuring. A guidance increase—particularly without a corresponding revenue opportunity—would pressure the operating-leverage thesis.
The market's attention has shifted sharply toward competition from perpetual futures. In June, the CFTC provided relief allowing designated contract markets to convert certain digital-commodity contracts into true perpetual futures. Exchange shares sold off as investors considered whether the structure could eventually extend beyond crypto and compete with established futures franchises. (cftc.gov)
CME has challenged the regulatory decision in court, arguing that perpetual contracts should be treated as swaps rather than traditional futures. (investing.com)
This is likely to dominate the Q&A. Investors will want management to address:
The bear case is that simpler, continuously traded contracts fragment retail and speculative liquidity. The bull case is that CME's institutional ecosystem—deep liquidity, physical or cash convergence, clearing, portfolio offsets and regulatory credibility—is difficult to replicate.
CME continues to broaden access to its markets through micro contracts, crypto, event contracts, prediction markets, cross-margining and planned cloud migration.
Recent evidence is encouraging:
However, the CFTC stayed CME's proposed launch of round-the-clock crude-oil trading in July pending further review.
Management should clarify the timeline for:
This will be CME's first earnings call since announcing that Terry Duffy will step down as CEO on March 1, 2027, become executive chairman, and be succeeded by current President and CFO Lynne Fitzpatrick.
The transition appears designed for continuity: Fitzpatrick has been with CME since 2006, became CFO in 2023 and president in 2024, while Duffy will remain involved as executive chairman. Nevertheless, investors may seek greater detail on strategic priorities, the future CFO appointment, capital allocation and who will lead the company's regulatory response.
The timing makes Fitzpatrick's commentary especially important: investors will be evaluating not only quarterly execution but also her willingness to defend CME's existing franchise while investing in newer retail and digital products.
CME paid approximately $2.7 billion in dividends and repurchased $536 million of stock during Q1. (cmegroup.com)
The share-price setup has changed materially since then. CME closed July 21 at approximately $237, down about 13% year to date and roughly 26% from its February high. Much of the exchange sector's decline followed the regulatory opening for perpetual futures.
That creates two questions:
An increased buyback pace could signal management confidence that the market is overstating the competitive threat. Investors should still avoid viewing repurchases as a substitute for a convincing strategic response.
The reported numbers should be respectable rather than spectacular. Q2 volume was slightly below last year's record, but June momentum, equity-index growth, market data and cash-market activity provide offsets. Consensus already reflects this normalization.
The stock reaction will probably depend less on whether adjusted EPS is a few cents above or below $2.93 and more on three issues:
The recent share-price decline has lowered expectations, but it also reflects a genuine strategic uncertainty. A clean quarter plus a forceful, credible competitive response could produce relief. A routine earnings beat without clarity on perpetuals may not be enough.